Key Stats for Grail Stock
- Price change for Grail stock: -47%
- $GRAL Share Price as of Feb. 22: $50
- 52-Week High: $119
- $GRAL Stock Price Target: $100
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
GRAIL (GRAL) stock suffered a devastating blow last week, plummeting 47% after the company’s landmark NHS-Galleri trial missed its primary endpoint.
The trial, which enrolled 142,000 participants in England over three years, failed to show a statistically significant reduction in combined Stage III and IV cancer diagnoses—the main goal the researchers hoped to achieve.
This is a major setback for the cancer detection company, which has been positioning its Galleri blood test as a breakthrough screening tool capable of detecting multiple types of cancer before symptoms appear.
The company spent years and substantial resources running what became the largest randomized trial ever conducted for a multi-cancer early detection test.
- The market’s reaction was swift and brutal. Investors who had been betting on positive trial results to unlock Medicare coverage and FDA approval saw their thesis crumble in a single trading session.
- GRAIL stock lost nearly half its value after data revealed the test couldn’t deliver the population-level stage shift needed to justify widespread adoption and reimbursement.
- That said, the results weren’t entirely negative.
- GRAIL reported a greater than 20% reduction in Stage IV cancer diagnoses in the second and third screening rounds for a pre-specified group of 12 deadly cancer types.
- The test also produced a fourfold improvement in overall cancer detection rates compared to standard screening alone and increased the number of Stage I-II cancers found.
See analysts’ growth forecasts and price targets for GRAL stock (It’s free!) >>>
What the Market Is Telling Us About GRAL Stock
The market’s severe reaction to GRAIL stock suggests investors view the primary endpoint miss as fatal to the company’s near-term commercial prospects.
Missing the trial’s main goal creates significant uncertainty about regulatory approval, payer coverage, and physician adoption—all critical factors for a diagnostic test company.
Wall Street analysts peppered management with questions about the prospects for FDA approval during the earnings call.
CEO Bob Ragusa and executives insisted the FDA’s focus on clinical performance and safety—not clinical utility—means the approval pathway remains intact.
They noted that their premarket approval application included only data from the first year of the NHS trial and the PATHFINDER 2 study, both of which showed strong test performance metrics.
- But investors aren’t buying that explanation, at least not yet.
- The reality is that Medicare and commercial payers typically require evidence of clinical utility before covering expensive screening tests.
- A trial designed to demonstrate population-level benefit that falls short raises serious questions about whether GRAIL can prove its test actually saves lives or just finds more cancers.
- Management announced plans to extend the trial follow-up by 6-12 months, hoping that more mature data will show a stronger effect.
- They also revealed they’re expanding their sales force based on “strong results”—a decision that seems different given the primary endpoint failure and will likely burn through additional cash while the reimbursement picture remains murky.
GRAIL stock now faces a difficult road ahead. The company maintains it has a cash runway into 2030, but with a market cap that’s been cut in half and significant questions about its commercial trajectory, investors are clearly reassessing whether this company can ever achieve profitability.
The FDA decision, expected in the coming months, will be critical. But even approval may not be enough if payers refuse to cover the test without the kind of clinical utility data the NHS-Galleri trial was supposed to provide.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does GRAL Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
